Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS (DNKI-4)
Randomized Comparative Study for Efficacy and Safety Evaluation of HLA-haploidentical Hematopoietic Cell Transplantation With or Without Post-transplant Allogeneic Donor-derived Natural Killer Cell Infusion in High-risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Sponsor: Asan Medical Center
Terminated
upon recommendation from the Data Monitoring Committee
Other terminated trials from Asan Medical Center
Other Acute Myelogenous Leukemia trials with similar outcome
This PHASE2 trial investigates Acute Myelogenous Leukemia and is currently terminated or withdrawn. Asan Medical Center leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Jul 2018 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .